Molecular glue: Difference between revisions
consistent citation formatting |
mNo edit summary Tags: references removed Visual edit |
||
Line 3: | Line 3: | ||
'''Molecular glue''' refers to a class of [[chemical compound]]s or [[molecule]]s that play a crucial role in binding and stabilizing [[Protein–protein interaction|protein-protein interactions]] in biological systems. These molecules act as "glue" by enhancing the affinity between proteins, ultimately influencing various cellular processes. Molecular glue compounds have gained significant attention in the fields of [[drug discovery]], [[chemical biology]], and [[fundamental research]] due to their potential to modulate protein interactions, and thus, impact various cellular pathways. They have unlocked avenues in medicine previously thought to be "undruggable". |
'''Molecular glue''' refers to a class of [[chemical compound]]s or [[molecule]]s that play a crucial role in binding and stabilizing [[Protein–protein interaction|protein-protein interactions]] in biological systems. These molecules act as "glue" by enhancing the affinity between proteins, ultimately influencing various cellular processes. Molecular glue compounds have gained significant attention in the fields of [[drug discovery]], [[chemical biology]], and [[fundamental research]] due to their potential to modulate protein interactions, and thus, impact various cellular pathways. They have unlocked avenues in medicine previously thought to be "undruggable". |
||
[[File:Auxin's mechanism of action, which led to the popularization of the term 'molecular glue.' Ub = ubiquitin; R = Rbx1; E2 = E2 ubiquitin-conjugating enzyme.png|thumb|Auxin's mechanism of action, which led to the popularization of the term 'molecular glue.'<ref>{{cite journal | vauthors = Tan X, Calderon-Villalobos LI, Sharon M, Zheng C, Robinson CV, Estelle M, Zheng N | title = Mechanism of auxin perception by the TIR1 ubiquitin ligase | journal = Nature | volume = 446 | issue = 7136 | pages = 640–645 | date = April 2007 | pmid = 17410169 | doi = 10.1038/nature05731 }}</ref> Ub = ubiquitin; R = Rbx1; E2 = E2 ubiquitin-conjugating enzyme.]] |
[[File:Auxin's mechanism of action, which led to the popularization of the term 'molecular glue.' Ub = ubiquitin; R = Rbx1; E2 = E2 ubiquitin-conjugating enzyme.png|thumb|Auxin's mechanism of action, which led to the popularization of the term 'molecular glue.'<ref name=":0">{{cite journal | vauthors = Tan X, Calderon-Villalobos LI, Sharon M, Zheng C, Robinson CV, Estelle M, Zheng N | title = Mechanism of auxin perception by the TIR1 ubiquitin ligase | journal = Nature | volume = 446 | issue = 7136 | pages = 640–645 | date = April 2007 | pmid = 17410169 | doi = 10.1038/nature05731 }}</ref> Ub = ubiquitin; R = Rbx1; E2 = E2 ubiquitin-conjugating enzyme.]] |
||
== History == |
== History == |
||
Line 13: | Line 13: | ||
The exploration of molecular glues took a significant turn in 1996 with the discovery that [[discodermolide]] stabilized the association of alpha and beta [[tubulin]] [[monomer]]s, functioning as a "molecular clamp" rather than inducing neo-associations.<ref name="Schreiber_2021" /> In 2000, the revelation that a synthetic compound, [[synstab-A]], could induce associations of native proteins marked a shift towards the discovery of non-natural molecular glues.<ref name="Schreiber_2021" /> |
The exploration of molecular glues took a significant turn in 1996 with the discovery that [[discodermolide]] stabilized the association of alpha and beta [[tubulin]] [[monomer]]s, functioning as a "molecular clamp" rather than inducing neo-associations.<ref name="Schreiber_2021" /> In 2000, the revelation that a synthetic compound, [[synstab-A]], could induce associations of native proteins marked a shift towards the discovery of non-natural molecular glues.<ref name="Schreiber_2021" /> |
||
In 2001, Kathleen Sakamoto, [[Craig M. Crews]] and [[Raymond J. Deshaies]] raised the concept of [[Proteolysis targeting chimera|PROTACs]], which consist of a heterobifunctional molecule with a ligand of an E3 ubiquitin ligase linked to a ligand of a target protein.<ref>{{cite journal | vauthors = Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ | title = Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 98 | issue = 15 | pages = 8554–8559 | date = July 2001 | pmid = 11438690 | pmc = 37474 | doi = 10.1073/pnas.141230798 | doi-access = free | bibcode = 2001PNAS...98.8554S }}</ref> PROTACs are synthetic CIPs acting as protein degraders. |
In 2001, Kathleen Sakamoto, [[Craig M. Crews]] and [[Raymond J. Deshaies]] raised the concept of [[Proteolysis targeting chimera|PROTACs]], which consist of a heterobifunctional molecule with a ligand of an E3 [[ubiquitin ligase]] linked to a ligand of a target protein.<ref>{{cite journal | vauthors = Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ | title = Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 98 | issue = 15 | pages = 8554–8559 | date = July 2001 | pmid = 11438690 | pmc = 37474 | doi = 10.1073/pnas.141230798 | doi-access = free | bibcode = 2001PNAS...98.8554S }}</ref> PROTACs are synthetic CIPs acting as protein degraders. |
||
In 2007, the term “molecular glue” became popularized after it was independently coined by Ning Zheng to describe the mechanism of action of [[auxin]], a class of plant hormones regulating many aspects of plant growth and development.<ref |
In 2007, the term “molecular glue” became popularized after it was independently coined by Ning Zheng to describe the mechanism of action of [[auxin]], a class of plant hormones regulating many aspects of plant growth and development.<ref name=":0" /> By promoting the interaction between a plant E3 ubiquitin ligase, TIR1, and its substrate proteins, auxin induces the degradation of a family of transcriptional repressors. Auxin is chemically known as indole-3-acetic acid and has a molecular weight of 175 dalton. Unlike PROTACs and immunosupressants such as CsA and FK506, auxin is a chemically simple and monovalent compound with drug-like properties obeying [[Lipinski's rule of five|Lipinski’s rule of five]]. With no detectable affinity to the polyubiquitination substrate proteins of TIR1, auxin leverages the intrinsic weak affinity between the E3 ligase and its substrate proteins to enable stable protein complex formation. The same mechanism of action is shared by [[jasmonate]], another plant hormone involved in wound and stress responses.<ref>{{Cite journal |last=Sheard |first=Laura B. |last2=Tan |first2=Xu |last3=Mao |first3=Haibin |last4=Withers |first4=John |last5=Ben-Nissan |first5=Gili |last6=Hinds |first6=Thomas R. |last7=Kobayashi |first7=Yuichi |last8=Hsu |first8=Fong-Fu |last9=Sharon |first9=Michal |last10=Browse |first10=John |last11=He |first11=Sheng Yang |last12=Rizo |first12=Josep |last13=Howe |first13=Gregg A. |last14=Zheng |first14=Ning |date=2010-11-18 |title=Jasmonate perception by inositol-phosphate-potentiated COI1-JAZ co-receptor |url=https://pubmed.ncbi.nlm.nih.gov/20927106 |journal=Nature |volume=468 |issue=7322 |pages=400–405 |doi=10.1038/nature09430 |issn=1476-4687 |pmc=2988090 |pmid=20927106}}</ref> The term “molecular glue” has since been used, particularly in the context of targeted [[Proteolysis|protein degradation]], to specifically describe monovalent compounds with drug-like properties capable of promoting productive protein-protein interactions, instead of CIPs in general. |
||
In 2013, the mechanism of [[thalidomide]] analogs as molecular glue degraders had been revealed.<ref name="www.biochempeg.com" /> Notably, [[thalidomide]], discovered as a [[CRBN]] ligand in 2010, and [[lenalidomide]] enhance the binding of [[Casein kinase 1|CK1α]] to the E3 ubiquitin ligase, solidifying their role as molecular glues.<ref name="www.biochempeg.com" /><ref name="Schreiber_2021" /> Subsequently, [[indisulam]] was identified as a molecular glue capable of degrading [[RBM39]] by targeting DCAF15 in 2017.<ref name="www.biochempeg.com" /> These compounds are considered molecular glues because of their monovalency and chemical simplicity, which are consistent with the definition proposed by Shiyun Cao and Ning Zheng.<ref>{{cite journal | vauthors = Cao S, Kang S, Mao H, Yao J, Gu L, Zheng N | title = Defining molecular glues with a dual-nanobody cannabidiol sensor | journal = Nature Communications | volume = 13 | issue = 1 | pages = 815 | date = February 2022 | pmid = 35145136 | pmc = 8831599 | doi = 10.1038/s41467-022-28507-1 | bibcode = 2022NatCo..13..815C }}</ref> Analogous to auxin, these compounds are distinct from PROTACs, displaying no detectable affinity to the substrate proteins of the E3 ubiquitin ligases. |
In 2013, the mechanism of [[thalidomide]] analogs as molecular glue degraders had been revealed.<ref name="www.biochempeg.com" /> Notably, [[thalidomide]], discovered as a [[CRBN]] ligand in 2010, and [[lenalidomide]] enhance the binding of [[Casein kinase 1|CK1α]] to the E3 ubiquitin ligase, solidifying their role as molecular glues.<ref name="www.biochempeg.com" /><ref name="Schreiber_2021" /> Subsequently, [[indisulam]] was identified as a molecular glue capable of degrading [[RBM39]] by targeting DCAF15 in 2017.<ref name="www.biochempeg.com" /> These compounds are considered molecular glues because of their monovalency and chemical simplicity, which are consistent with the definition proposed by Shiyun Cao and Ning Zheng.<ref>{{cite journal | vauthors = Cao S, Kang S, Mao H, Yao J, Gu L, Zheng N | title = Defining molecular glues with a dual-nanobody cannabidiol sensor | journal = Nature Communications | volume = 13 | issue = 1 | pages = 815 | date = February 2022 | pmid = 35145136 | pmc = 8831599 | doi = 10.1038/s41467-022-28507-1 | bibcode = 2022NatCo..13..815C }}</ref> Analogous to auxin, these compounds are distinct from PROTACs, displaying no detectable affinity to the substrate proteins of the E3 ubiquitin ligases. |
||
Line 29: | Line 29: | ||
Molecular glue compounds are typically [[small molecule]]s that can bridge interactions between proteins. They often have specific [[binding site]]s on their target proteins and can enhance the association between these proteins. They do so by changing the surfaces of the proteins, encouraging binding between them when they would not usually interact. Molecular glue can enhance the stability of [[protein complex]]es, making them more resistant to [[Dissociation (chemistry)|dissociation]]. This can have a profound impact on cellular processes, as many biological functions are carried out by protein complexes. By influencing [[Protein–protein interaction|protein-protein interactions]], molecular glue can modify the functions, localization or stability of the target proteins. This can lead to both therapeutic and research applications.<ref>{{cite journal | vauthors = Soini L, Leysen S, Davis J, Ottmann C | title = Molecular glues to stabilise protein-protein interactions | journal = Current Opinion in Chemical Biology | volume = 69 | pages = 102169 | date = August 2022 | pmid = 35749929 | doi = 10.1016/j.cbpa.2022.102169 }}</ref> |
Molecular glue compounds are typically [[small molecule]]s that can bridge interactions between proteins. They often have specific [[binding site]]s on their target proteins and can enhance the association between these proteins. They do so by changing the surfaces of the proteins, encouraging binding between them when they would not usually interact. Molecular glue can enhance the stability of [[protein complex]]es, making them more resistant to [[Dissociation (chemistry)|dissociation]]. This can have a profound impact on cellular processes, as many biological functions are carried out by protein complexes. By influencing [[Protein–protein interaction|protein-protein interactions]], molecular glue can modify the functions, localization or stability of the target proteins. This can lead to both therapeutic and research applications.<ref>{{cite journal | vauthors = Soini L, Leysen S, Davis J, Ottmann C | title = Molecular glues to stabilise protein-protein interactions | journal = Current Opinion in Chemical Biology | volume = 69 | pages = 102169 | date = August 2022 | pmid = 35749929 | doi = 10.1016/j.cbpa.2022.102169 }}</ref> |
||
In the current era, molecular glues have become a more commonly utilized approach for targeted [[Proteolysis|protein degradation]], offering advantages over traditional [[small molecule drugs]] and [[PROTACs]]. The recognition of substrates by [[E3 Ubiquitin Ligase|E3 ubiquitin ligases]], governed by [[protein-protein interactions]] (PPIs), plays a critical role in cellular function.<ref name="Simonetta_2019">{{cite journal | vauthors = Simonetta KR, Taygerly J, Boyle K, Basham SE, Padovani C, Lou Y, Cummins TJ, Yung SL, von Soly SK, Kayser F, Kuriyan J, Rape M, Cardozo M, Gallop MA, Bence NF, Barsanti PA, Saha A | title = Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction | journal = Nature Communications | volume = 10 | issue = 1 | pages = 1402 | date = March 2019 | pmid = 30926793 | pmc = 6441019 | doi = 10.1038/s41467-019-09358-9 | bibcode = 2019NatCo..10.1402S }}</ref> There is significant therapeutic potential in developing small molecules that modulate these interactions, especially in the context of hard-to-drug proteins. A recent study reported the identification and rational design of potent [[small molecule]]s acting as molecular glues to enhance the interaction between an [[oncogenic]] [[transcription factor]], [[β-Catenin]], and its cognate [[E3 ligase]], [[ |
In the current era, molecular glues have become a more commonly utilized approach for targeted [[Proteolysis|protein degradation]], offering advantages over traditional [[small molecule drugs]] and [[PROTACs]]. The recognition of substrates by [[E3 Ubiquitin Ligase|E3 ubiquitin ligases]], governed by [[protein-protein interactions]] (PPIs), plays a critical role in cellular function.<ref name="Simonetta_2019">{{cite journal | vauthors = Simonetta KR, Taygerly J, Boyle K, Basham SE, Padovani C, Lou Y, Cummins TJ, Yung SL, von Soly SK, Kayser F, Kuriyan J, Rape M, Cardozo M, Gallop MA, Bence NF, Barsanti PA, Saha A | title = Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction | journal = Nature Communications | volume = 10 | issue = 1 | pages = 1402 | date = March 2019 | pmid = 30926793 | pmc = 6441019 | doi = 10.1038/s41467-019-09358-9 | bibcode = 2019NatCo..10.1402S }}</ref> There is significant therapeutic potential in developing small molecules that modulate these interactions, especially in the context of hard-to-drug proteins. A recent study reported the identification and rational design of potent [[small molecule]]s acting as molecular glues to enhance the interaction between an [[oncogenic]] [[transcription factor]], [[β-Catenin]], and its cognate [[E3 ligase]], SCF[[BTRC (gene)|β-TrCP]].<ref name="Simonetta_2019" /> These enhancers demonstrated the ability to potentiate [[ubiquitylation]] and induce the degradation of mutant [[β-Catenin]] both [[in vitro]] and in cellular systems. Unlike [[PROTACs]], these drug-like [[small molecule]]s insert into a naturally occurring [[Protein-protein interaction|PPI interface]], optimizing contacts for both the [[Substrate (chemistry)|substrate]] and [[ligase]] within a single molecular entity.<ref name="Simonetta_2019" /> |
||
Molecular glues offer a unique advantage in degrading non-ligand-bound proteins by promoting the PPI between [[ubiquitin ligase]] and the target protein.<ref name="Simonetta_2019" /> Notably, molecular glues exhibit superior therapeutic effects compared to small molecule drugs. This is attributed to their lower [[molecular weight]], higher [[cell permeability]], and better oral absorption, aligning with the "Five Rules for Drugs".<ref name="Simonetta_2019" /> In contrast, [[PROTACs]] face challenges such as high [[molecular weight]], poor [[cell permeability]], and unfavorable [[Pharmacokinetics|pharmacokinetic]] characteristics, hindering their [[clinical development]].<ref name="Simonetta_2019" /> |
Molecular glues offer a unique advantage in degrading non-ligand-bound proteins by promoting the PPI between [[ubiquitin ligase]] and the target protein.<ref name="Simonetta_2019" /> Notably, molecular glues exhibit superior therapeutic effects compared to small molecule drugs. This is attributed to their lower [[molecular weight]], higher [[cell permeability]], and better oral absorption, aligning with the "Five Rules for Drugs".<ref name="Simonetta_2019" /> In contrast, [[PROTACs]] face challenges such as high [[molecular weight]], poor [[cell permeability]], and unfavorable [[Pharmacokinetics|pharmacokinetic]] characteristics, hindering their [[clinical development]].<ref name="Simonetta_2019" /> |
||
Both [[PROTACs]] and molecular glues are integral to targeted [[Proteolysis|protein degradation]] technology based on the [[Ubiquitin proteasome pathway|ubiquitin-proteasome]] system.<ref name="www.biochempeg.com" /> While [[PROTACs]] recruit [[ubiquitin ligase]]s to induce the degradation of target proteins, molecular glues modify the surface of [[ubiquitin ligase]]s, promoting [[Protein–protein interaction|protein-protein interactions]] (PPIs) between [[E3 ubiquitin ligase]] and the target protein.<ref name="www.biochempeg.com" /> Molecular glues are particularly promising for degrading hard-to-drug proteins, showcasing a paradigm shift in drug development for targeted [[protein degradation]].<ref name="Simonetta_2019" /> |
|||
Recent advances in the field have led to the development of [[BCL6]] and [[Cyclin K]] Degraders, which leverage both protein-ligand and [[Protein protein interfaces|protein-protein interfaces]] for tight complex formation.<ref name="Kozicka_2021">{{cite journal | vauthors = Kozicka Z, Thomä NH | title = Haven't got a glue: Protein surface variation for the design of molecular glue degraders | journal = Cell Chemical Biology | volume = 28 | issue = 7 | pages = 1032–1047 | date = July 2021 | pmid = 33930325 | doi = 10.1016/j.chembiol.2021.04.009 | doi-access = free }}</ref> These molecular glue degrader drugs are characterized by their small size (<500 [[Dalton (unit)|Da]]) and exhibit high affinity between the [[ligase]] and [[neosubstrate]] in the presence of the [[small molecule]].<ref name="Kozicka_2021" /> The complementary nature of [[Protein–protein interaction|protein-protein]] interfaces suggests the potential for natural interactions between the two proteins even in the absence of the compound.<ref name="Kozicka_2021" /> |
Recent advances in the field have led to the development of [[BCL6]] and [[Cyclin K]] Degraders, which leverage both protein-ligand and [[Protein protein interfaces|protein-protein interfaces]] for tight complex formation.<ref name="Kozicka_2021">{{cite journal | vauthors = Kozicka Z, Thomä NH | title = Haven't got a glue: Protein surface variation for the design of molecular glue degraders | journal = Cell Chemical Biology | volume = 28 | issue = 7 | pages = 1032–1047 | date = July 2021 | pmid = 33930325 | doi = 10.1016/j.chembiol.2021.04.009 | doi-access = free }}</ref> These molecular glue degrader drugs are characterized by their small size (<500 [[Dalton (unit)|Da]]) and exhibit high affinity between the [[ligase]] and [[neosubstrate]] in the presence of the [[small molecule]].<ref name="Kozicka_2021" /> The complementary nature of [[Protein–protein interaction|protein-protein]] interfaces suggests the potential for natural interactions between the two proteins even in the absence of the compound.<ref name="Kozicka_2021" /> |
||
The identification of molecular-glue-type degraders has typically occurred retrospectively and serendipitously, but recent chemical-profiling approaches aim to prospectively identify [[small molecule]]s acting as molecular glues.<ref name="den Besten_2020">{{cite journal |vauthors=den Besten W, Lipford JR |date=November 2020 |title=Prospecting for molecular glues |journal=Nature Chemical Biology |volume=16 |issue=11 |pages=1157–1158 |doi=10.1038/s41589-020-0620-z |pmid=32747810 |s2cid=220947901}}</ref> Researchers are exploring alternative [[small molecule]]s, like CR8, to induce [[ubiquitination]] of targets in a [[top-down approach]] for induced [[Proteolysis|protein degradation]].<ref name="Tian_2021">{{cite journal | vauthors = Tian C, Burgess K | title = PROTAC Compatibilities, Degrading Cell-Surface Receptors, and the Sticky Problem of Finding a Molecular Glue | journal = ChemMedChem | volume = 16 | issue = 2 | pages = 316–318 | date = January 2021 | pmid = 33112038 | doi = 10.1002/cmdc.202000683 | s2cid = 225100015 }}</ref> CR8, identified through correlation analysis, operates via protein degradation by inducing [[ubiquitination]] through a molecular glue-like mechanism. The study emphasizes the potential of [[small molecule]]s beyond [[PROTACs]] for targeted [[protein degradation]].<ref name="Tian_2021" /> |
|||
Researchers are exploring alternative [[small molecule]]s, like CR8, to induce [[ubiquitination]] of targets in a [[top-down approach]] for induced [[Proteolysis|protein degradation]].<ref name="Tian_2021">{{cite journal | vauthors = Tian C, Burgess K | title = PROTAC Compatibilities, Degrading Cell-Surface Receptors, and the Sticky Problem of Finding a Molecular Glue | journal = ChemMedChem | volume = 16 | issue = 2 | pages = 316–318 | date = January 2021 | pmid = 33112038 | doi = 10.1002/cmdc.202000683 | s2cid = 225100015 }}</ref> CR8, identified through correlation analysis, operates via protein degradation by inducing [[ubiquitination]] through a molecular glue-like mechanism. The study emphasizes the potential of [[small molecule]]s beyond [[PROTACs]] for targeted [[protein degradation]].<ref name="Tian_2021" /> |
|||
There have also been reports of molecular glues that stabilize protein-RNA interactions<ref>{{cite journal | vauthors = Childs-Disney JL, Yang X, Gibaut QM, Tong Y, Batey RT, Disney MD | title = Targeting RNA structures with small molecules | journal = Nature Reviews. Drug Discovery | volume = 21 | issue = 10 | pages = 736–762 | date = October 2022 | pmid = 35941229 | pmc = 9360655 | doi = 10.1038/s41573-022-00521-4 }}</ref> and protein-lipid interactions.<ref>{{cite journal | vauthors = Pahil KS, Gilman MS, Baidin V, Clairfeuille T, Mattei P, Bieniossek C, Dey F, Muri D, Baettig R, Lobritz M, Bradley K, Kruse AC, Kahne D | title = A new antibiotic traps lipopolysaccharide in its intermembrane transporter | journal = Nature | volume = 625 | issue = 7995 | pages = 572–577 | date = January 2024 | pmid = 38172635 | pmc = 10794137 | doi = 10.1038/s41586-023-06799-7 | doi-access = free | bibcode = 2024Natur.625..572P }}</ref> |
There have also been reports of molecular glues that stabilize protein-RNA interactions<ref>{{cite journal | vauthors = Childs-Disney JL, Yang X, Gibaut QM, Tong Y, Batey RT, Disney MD | title = Targeting RNA structures with small molecules | journal = Nature Reviews. Drug Discovery | volume = 21 | issue = 10 | pages = 736–762 | date = October 2022 | pmid = 35941229 | pmc = 9360655 | doi = 10.1038/s41573-022-00521-4 }}</ref> and protein-lipid interactions.<ref>{{cite journal | vauthors = Pahil KS, Gilman MS, Baidin V, Clairfeuille T, Mattei P, Bieniossek C, Dey F, Muri D, Baettig R, Lobritz M, Bradley K, Kruse AC, Kahne D | title = A new antibiotic traps lipopolysaccharide in its intermembrane transporter | journal = Nature | volume = 625 | issue = 7995 | pages = 572–577 | date = January 2024 | pmid = 38172635 | pmc = 10794137 | doi = 10.1038/s41586-023-06799-7 | doi-access = free | bibcode = 2024Natur.625..572P }}</ref> |
Revision as of 10:38, 25 May 2024
Molecular glue refers to a class of chemical compounds or molecules that play a crucial role in binding and stabilizing protein-protein interactions in biological systems. These molecules act as "glue" by enhancing the affinity between proteins, ultimately influencing various cellular processes. Molecular glue compounds have gained significant attention in the fields of drug discovery, chemical biology, and fundamental research due to their potential to modulate protein interactions, and thus, impact various cellular pathways. They have unlocked avenues in medicine previously thought to be "undruggable".
![](http://upload.wikimedia.org/wikipedia/commons/thumb/8/85/Auxin%27s_mechanism_of_action%2C_which_led_to_the_popularization_of_the_term_%27molecular_glue.%27_Ub_%3D_ubiquitin%3B_R_%3D_Rbx1%3B_E2_%3D_E2_ubiquitin-conjugating_enzyme.png/220px-Auxin%27s_mechanism_of_action%2C_which_led_to_the_popularization_of_the_term_%27molecular_glue.%27_Ub_%3D_ubiquitin%3B_R_%3D_Rbx1%3B_E2_%3D_E2_ubiquitin-conjugating_enzyme.png)
History
The concept of "molecular glue" originated in the late 20th century, with immunosuppressants like cyclosporine A (CsA) and FK506 identified as pioneering examples.[2] CsA, discovered in 1971 during routine screening for antifungal antibiotics, exhibited immunosuppressive properties by inhibiting the peptidyl–prolyl isomerase activity of cyclophilin, ultimately preventing organ transplant rejections.[3] By 1979, CsA was used clinically, and FK506 (tacrolimus), discovered in 1987 by Fujisawa, emerged as a more potent immunosuppressant.[3] The ensuing 4-year race to understand CsA and FK506's mechanisms led to the identification of FKBP12 as a common binding partner, marking the birth of the "molecular glue" concept.[3] The term molecular glue found its way into publications in 1992, highlighting the selective gluing of specific proteins by antigenic peptides, akin to immunosuppressants acting as docking assemblies.[3] The term, however, remained esoteric and hidden from keyword searches.
In the early 1990s, researchers delved into understanding the role of proximity in biological processes.[3] The creation of synthetic "chemical inducers of proximity" (CIPs), such as FK1012, opened the door to more complex molecular glues.[3] Rimiducid, a purposefully synthesized molecular glue, demonstrated its effectiveness in eliminating graft-versus-host disease by inducing dimerization of death-receptor fusion targets.[3]
The exploration of molecular glues took a significant turn in 1996 with the discovery that discodermolide stabilized the association of alpha and beta tubulin monomers, functioning as a "molecular clamp" rather than inducing neo-associations.[3] In 2000, the revelation that a synthetic compound, synstab-A, could induce associations of native proteins marked a shift towards the discovery of non-natural molecular glues.[3]
In 2001, Kathleen Sakamoto, Craig M. Crews and Raymond J. Deshaies raised the concept of PROTACs, which consist of a heterobifunctional molecule with a ligand of an E3 ubiquitin ligase linked to a ligand of a target protein.[4] PROTACs are synthetic CIPs acting as protein degraders.
In 2007, the term “molecular glue” became popularized after it was independently coined by Ning Zheng to describe the mechanism of action of auxin, a class of plant hormones regulating many aspects of plant growth and development.[1] By promoting the interaction between a plant E3 ubiquitin ligase, TIR1, and its substrate proteins, auxin induces the degradation of a family of transcriptional repressors. Auxin is chemically known as indole-3-acetic acid and has a molecular weight of 175 dalton. Unlike PROTACs and immunosupressants such as CsA and FK506, auxin is a chemically simple and monovalent compound with drug-like properties obeying Lipinski’s rule of five. With no detectable affinity to the polyubiquitination substrate proteins of TIR1, auxin leverages the intrinsic weak affinity between the E3 ligase and its substrate proteins to enable stable protein complex formation. The same mechanism of action is shared by jasmonate, another plant hormone involved in wound and stress responses.[5] The term “molecular glue” has since been used, particularly in the context of targeted protein degradation, to specifically describe monovalent compounds with drug-like properties capable of promoting productive protein-protein interactions, instead of CIPs in general.
In 2013, the mechanism of thalidomide analogs as molecular glue degraders had been revealed.[2] Notably, thalidomide, discovered as a CRBN ligand in 2010, and lenalidomide enhance the binding of CK1α to the E3 ubiquitin ligase, solidifying their role as molecular glues.[2][3] Subsequently, indisulam was identified as a molecular glue capable of degrading RBM39 by targeting DCAF15 in 2017.[2] These compounds are considered molecular glues because of their monovalency and chemical simplicity, which are consistent with the definition proposed by Shiyun Cao and Ning Zheng.[6] Analogous to auxin, these compounds are distinct from PROTACs, displaying no detectable affinity to the substrate proteins of the E3 ubiquitin ligases.
The year 2020 saw the discovery of autophagic molecular degraders and the identification of BI-3802 as a molecular glue inducing the polymerization and degradation of BCL6.[2] Additionally, chemogenomic screening revealed structurally diverse molecular glue degraders targeting cyclin K.[2] The discovery that manumycin polyketides acted as molecular glues, fostering interactions between UBR7 and P53, further expanded the understanding of molecular glue functions.[2]
In recent years, the field of molecular glues has witnessed an explosion of discoveries targeting native proteins.[3] Examples include synthetic FKBP12-binding glues like FKBP12-rapadocin, which targets the adenosine transporter SLC29A1.[3] Thalidomide and lenalidomide, classified as immunomodulatory drugs (IMiDs), were identified as small-molecule glues inducing ubiquitination of transcription factors via E3 ligase complexes.[3] Computational searches for molecular-glue degraders in 2020 added novel probes to the ever-expanding landscape of molecular glues.[3]
The transformative power of molecular glues in medicine became evident as drugs like sandimmune, tacrolimus, sirolimus, thalidomide, lenalidomide, and taxotere proved effective.[3] The concept of inducing protein associations has shown promise in gene therapy and has become a potent tool in understanding cell circuitry.[3] As the field continues to advance, the discovery of new molecular glues offers the potential to reshape drug discovery and overcome previously labeled "undruggable" targets.[3] The future of molecular glues holds promise for rewiring cellular circuitry and providing innovative solutions in precision medicine.[3]
Properties and mechanisms
Molecular glue compounds are typically small molecules that can bridge interactions between proteins. They often have specific binding sites on their target proteins and can enhance the association between these proteins. They do so by changing the surfaces of the proteins, encouraging binding between them when they would not usually interact. Molecular glue can enhance the stability of protein complexes, making them more resistant to dissociation. This can have a profound impact on cellular processes, as many biological functions are carried out by protein complexes. By influencing protein-protein interactions, molecular glue can modify the functions, localization or stability of the target proteins. This can lead to both therapeutic and research applications.[7]
In the current era, molecular glues have become a more commonly utilized approach for targeted protein degradation, offering advantages over traditional small molecule drugs and PROTACs. The recognition of substrates by E3 ubiquitin ligases, governed by protein-protein interactions (PPIs), plays a critical role in cellular function.[8] There is significant therapeutic potential in developing small molecules that modulate these interactions, especially in the context of hard-to-drug proteins. A recent study reported the identification and rational design of potent small molecules acting as molecular glues to enhance the interaction between an oncogenic transcription factor, β-Catenin, and its cognate E3 ligase, SCFβ-TrCP.[8] These enhancers demonstrated the ability to potentiate ubiquitylation and induce the degradation of mutant β-Catenin both in vitro and in cellular systems. Unlike PROTACs, these drug-like small molecules insert into a naturally occurring PPI interface, optimizing contacts for both the substrate and ligase within a single molecular entity.[8]
Molecular glues offer a unique advantage in degrading non-ligand-bound proteins by promoting the PPI between ubiquitin ligase and the target protein.[8] Notably, molecular glues exhibit superior therapeutic effects compared to small molecule drugs. This is attributed to their lower molecular weight, higher cell permeability, and better oral absorption, aligning with the "Five Rules for Drugs".[8] In contrast, PROTACs face challenges such as high molecular weight, poor cell permeability, and unfavorable pharmacokinetic characteristics, hindering their clinical development.[8]
Recent advances in the field have led to the development of BCL6 and Cyclin K Degraders, which leverage both protein-ligand and protein-protein interfaces for tight complex formation.[9] These molecular glue degrader drugs are characterized by their small size (<500 Da) and exhibit high affinity between the ligase and neosubstrate in the presence of the small molecule.[9] The complementary nature of protein-protein interfaces suggests the potential for natural interactions between the two proteins even in the absence of the compound.[9]
The identification of molecular-glue-type degraders has typically occurred retrospectively and serendipitously, but recent chemical-profiling approaches aim to prospectively identify small molecules acting as molecular glues.[10] Researchers are exploring alternative small molecules, like CR8, to induce ubiquitination of targets in a top-down approach for induced protein degradation.[11] CR8, identified through correlation analysis, operates via protein degradation by inducing ubiquitination through a molecular glue-like mechanism. The study emphasizes the potential of small molecules beyond PROTACs for targeted protein degradation.[11]
There have also been reports of molecular glues that stabilize protein-RNA interactions[12] and protein-lipid interactions.[13]
Applications
Cancer therapy
Molecular glue compounds have demonstrated significant potential in cancer treatment by influencing protein-protein interactions (PPIs) and subsequently modulating pathways promoting cancer growth. These compounds act as targeted protein degraders, contributing to the development of innovative cancer therapies.[14] The high efficacy of small-molecule molecular glue compounds in cancer treatment is notable, as they can interact with and control multiple key protein targets involved in cancer etiology.[14] This approach, with its wider range of action and ability to target "undruggable" proteins, holds promise for overcoming drug resistance and changing the landscape of drug development in cancer therapy.[14]
Neurodegenerative diseases
Molecular glue compounds are being explored for their potential in influencing protein interactions associated with neurodegenerative diseases such as Alzheimer's and Parkinson's. By modulating these interactions, researchers aim to develop treatments that could slow or prevent the progression of these diseases.[14] Additionally, the versatility of small-molecule molecular glue compounds in targeting various proteins implicated in disease mechanisms provides a valuable avenue for unraveling the complexities of neurodegenerative disorders.[14]
Antiviral research
Molecular glue compounds, particularly those involved in targeted protein degradation (TPD), offer a novel strategy for inhibiting viral protein interactions and combating viral infections.[15] Unlike traditional direct-acting antivirals (DAAs), TPD-based molecules exert their pharmacological activity through event-driven mechanisms, inducing target degradation. This unique approach can lead to prolonged pharmacodynamic efficacy with lower pharmacokinetic exposure, potentially reducing toxicity and the risk of antiviral resistance.[15] The protein-protein interactions induced by TPD molecules may also enhance selectivity, making them a promising avenue for antiviral research.[15]
Chemical biology
Molecular glue serves as a valuable tool in chemical biology, enabling scientists to manipulate and understand protein functions and interactions in a controlled manner.[14] The emergence of targeted protein degradation as a modality in drug discovery has further expanded the applications of molecular glue in chemical biology.[15] The ability of small-molecule molecular glue compounds to induce iterative cycles of target degradation provides researchers with a powerful method for studying protein-protein interactions and opens avenues for drug development in various human diseases.[15]
Challenges and future prospects
While molecular glue compounds hold great potential in various fields, there are challenges to overcome. Ensuring the specificity of these compounds and minimizing off-target effects is essential. Additionally, understanding the long-term consequences of manipulating protein interactions is crucial for their safe and effective application in medicine.
Ongoing research in molecular glue is unlocking new compounds and insights into their mechanisms. With an expanding understanding of protein-protein interactions, molecular glue holds significant promise across biology, medicine, and chemistry, potentially revolutionizing cellular processes and advancing innovative disease treatments. As this field progresses, it may open new therapeutic avenues and deepen our understanding of life's molecular intricacies.
References
- ^ a b Tan X, Calderon-Villalobos LI, Sharon M, Zheng C, Robinson CV, Estelle M, et al. (April 2007). "Mechanism of auxin perception by the TIR1 ubiquitin ligase". Nature. 446 (7136): 640–645. doi:10.1038/nature05731. PMID 17410169.
- ^ a b c d e f g "Molecular Glues: A New Dawn After PROTAC | Biopharma PEG". www.biochempeg.com. Retrieved 2023-11-14.
- ^ a b c d e f g h i j k l m n o p q r Schreiber SL (January 2021). "The Rise of Molecular Glues". Cell. 184 (1): 3–9. doi:10.1016/j.cell.2020.12.020. PMID 33417864.
- ^ Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ (July 2001). "Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation". Proceedings of the National Academy of Sciences of the United States of America. 98 (15): 8554–8559. Bibcode:2001PNAS...98.8554S. doi:10.1073/pnas.141230798. PMC 37474. PMID 11438690.
- ^ Sheard LB, Tan X, Mao H, Withers J, Ben-Nissan G, Hinds TR, et al. (2010-11-18). "Jasmonate perception by inositol-phosphate-potentiated COI1-JAZ co-receptor". Nature. 468 (7322): 400–405. doi:10.1038/nature09430. ISSN 1476-4687. PMC 2988090. PMID 20927106.
- ^ Cao S, Kang S, Mao H, Yao J, Gu L, Zheng N (February 2022). "Defining molecular glues with a dual-nanobody cannabidiol sensor". Nature Communications. 13 (1): 815. Bibcode:2022NatCo..13..815C. doi:10.1038/s41467-022-28507-1. PMC 8831599. PMID 35145136.
- ^ Soini L, Leysen S, Davis J, Ottmann C (August 2022). "Molecular glues to stabilise protein-protein interactions". Current Opinion in Chemical Biology. 69: 102169. doi:10.1016/j.cbpa.2022.102169. PMID 35749929.
- ^ a b c d e f Simonetta KR, Taygerly J, Boyle K, Basham SE, Padovani C, Lou Y, et al. (March 2019). "Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction". Nature Communications. 10 (1): 1402. Bibcode:2019NatCo..10.1402S. doi:10.1038/s41467-019-09358-9. PMC 6441019. PMID 30926793.
- ^ a b c Kozicka Z, Thomä NH (July 2021). "Haven't got a glue: Protein surface variation for the design of molecular glue degraders". Cell Chemical Biology. 28 (7): 1032–1047. doi:10.1016/j.chembiol.2021.04.009. PMID 33930325.
- ^ den Besten W, Lipford JR (November 2020). "Prospecting for molecular glues". Nature Chemical Biology. 16 (11): 1157–1158. doi:10.1038/s41589-020-0620-z. PMID 32747810. S2CID 220947901.
- ^ a b Tian C, Burgess K (January 2021). "PROTAC Compatibilities, Degrading Cell-Surface Receptors, and the Sticky Problem of Finding a Molecular Glue". ChemMedChem. 16 (2): 316–318. doi:10.1002/cmdc.202000683. PMID 33112038. S2CID 225100015.
- ^ Childs-Disney JL, Yang X, Gibaut QM, Tong Y, Batey RT, Disney MD (October 2022). "Targeting RNA structures with small molecules". Nature Reviews. Drug Discovery. 21 (10): 736–762. doi:10.1038/s41573-022-00521-4. PMC 9360655. PMID 35941229.
- ^ Pahil KS, Gilman MS, Baidin V, Clairfeuille T, Mattei P, Bieniossek C, et al. (January 2024). "A new antibiotic traps lipopolysaccharide in its intermembrane transporter". Nature. 625 (7995): 572–577. Bibcode:2024Natur.625..572P. doi:10.1038/s41586-023-06799-7. PMC 10794137. PMID 38172635.
- ^ a b c d e f Li F, Aljahdali IA, Ling X (June 2022). "Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein-Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases". International Journal of Molecular Sciences. 23 (11): 6206. doi:10.3390/ijms23116206. PMC 9181451. PMID 35682885.
- ^ a b c d e Chakravarty A, Yang PL (February 2023). "Targeted protein degradation as an antiviral approach". Antiviral Research. Special Issue in Honor of Dr. Mike Bray on his retirement as the Editor-in-Chief of Antiviral Research. 210: 105480. doi:10.1016/j.antiviral.2022.105480. PMC 10178900. PMID 36567024.